Sjuts Dustin S 4
4 · Revance Therapeutics, Inc. · Filed Feb 16, 2023
Insider Transaction Report
Form 4
Sjuts Dustin S
Chief Commercial Officer
Transactions
- Tax Payment
Common Stock
2023-02-15$33.21/sh−2,766$91,859→ 93,046 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the "RSA") for 6,667 shares. The RSA vested in three equal annual installments from February 15, 2020.